OralTopicalDosed ingredientTherapeutic flag
Nicotine
CAS 54-11-5
Nicotine (CAS 54-11-5) is a Phase 4 pharmaceutical compound with 28 bioactivity targets and 1,039 adverse event associations.
SOURCE
NLM DailyMed
Label records
0
SOURCE
EMBL-EBI ChEMBL
Bioactivity
48
SOURCE
DrugCentral / FAERS
Adverse signals
1,039
SOURCE
IUPHAR / PharmGKB
PubMed IDs
45
SOURCE
ChEMBL 36
B25820EEF0F0
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Nicotine
CAS Number
54-11-5
UNII
6M3C89ZY6R
InChIKey
SNICXCGAKADSCV-JTQLQIEISA-N
ChEMBL ID
CHEMBL3
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
dosed ingredientnatural productoraltherapeutic flagtopical
SOURCE
ChEMBL 36
B25820EEF0F0
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL3 | Small molecule
SOURCE
ChEMBL 36 activities + assays
48 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Ki | 1639.901333152174 nM | 348 | - |
| - | EC50 | 13601.846428571429 nM | 89 | - |
| - | IC50 | 5452.375151515152 nM | 63 | - |
| - | AC50 | 29733.396666666667 nM | 30 | - |
| - | Potency | 17791.785294117646 nM | 23 | - |
| - | Kd | 7104.335411764706 nM | 13 | - |
| Neuronal acetylcholine receptor subunit alpha-7 Ion channel |
Ki | 5.39 | - | Homo sapiens |
| Potassium voltage-gated channel subfamily D member 3 Ion channel |
IC50 | 7.4 | - | Homo sapiens |
| Cytochrome P450 2A6 Enzyme |
IC50 | 5.356 | - | Homo sapiens |
| Acetylcholine-binding protein Unclassified |
Ki | 7.2 | - | Lymnaea stagnalis |
| Transient receptor potential cation channel subfamily A member 1 Ion channel |
EC50 | 4.8 | - | Homo sapiens |
| Acetylcholine receptor subunit delta Ion channel |
Ki | 9 | - | Torpedo californica |
| Neuronal acetylcholine receptor subunit alpha-4 Ion channel |
Ki | 9.03 | - | Rattus norvegicus |
| Neuronal acetylcholine receptor subunit alpha-7 Ion channel |
Ki | 6.89 | - | Rattus norvegicus |
| Neuronal acetylcholine receptor subunit alpha-7 Ion channel |
Ki | 6.61 | - | Mus musculus |
| Neuronal acetylcholine receptor subunit alpha-9 Ion channel |
Kd | 8.3 | - | Rattus norvegicus |
| Neuronal acetylcholine receptor subunit beta-4 Ion channel |
Ki | 7.14 | - | Rattus norvegicus |
| Neuronal acetylcholine receptor subunit alpha-3 Ion channel |
Ki | 7.33 | - | Rattus norvegicus |
| Neuronal acetylcholine receptor subunit alpha-2 Ion channel |
Ki | 7.92 | - | Rattus norvegicus |
| Soluble acetylcholine receptor Unclassified |
Ki | 7.52 | - | Aplysia californica |
| Acetylcholine receptor subunit alpha Ion channel |
IC50 | 4.64 | - | Torpedo californica |
| Lycopene cyclase Enzyme |
IC50 | 5.32 | - | Pantoea ananas |
| Nicotinic acetylcholine receptor alpha 5 subunit Ion channel |
Ki | 5.61 | - | Musca domestica |
| Acetylcholine receptor subunit beta-like 2 Ion channel |
Ki | 5.57 | - | Drosophila melanogaster |
| Neuronal acetylcholine receptor subunit alpha-4 Ion channel |
Ki | 8.72 | - | Gallus gallus |
| Neuronal acetylcholine receptor subunit alpha-4 Ion channel |
IC50 | 8.15 | - | Mus musculus |
| Neuronal acetylcholine receptor; alpha2/beta2 Ion channel |
Ki | 8.26 | - | Rattus norvegicus |
| Neuronal acetylcholine receptor; alpha3/beta2 Ion channel |
Ki | 9 | - | Rattus norvegicus |
| Neuronal acetylcholine receptor; alpha3/beta4 Ion channel |
Ki | 6.7 | - | Rattus norvegicus |
| Neuronal acetylcholine receptor; alpha4/beta2 Ion channel |
Kd | 9.4 | - | Rattus norvegicus |
| Neuronal acetylcholine receptor; alpha4/beta4 Ion channel |
Ki | 8.26 | - | Rattus norvegicus |
| Neuronal acetylcholine receptor; alpha2/beta4 Ion channel |
Ki | 7.15 | - | Homo sapiens |
| Neuronal acetylcholine receptor Ion channel |
Kd | 11 | - | Rattus norvegicus |
| Neuronal acetylcholine receptor; alpha2/beta2 Ion channel |
Ki | 8.26 | - | Homo sapiens |
| Neuronal acetylcholine receptor; alpha4/beta2 Ion channel |
Ki | 8.56 | - | Homo sapiens |
| Neuronal acetylcholine receptor; alpha3/beta4 Ion channel |
Ki | 5.95 | - | Homo sapiens |
| Neuronal acetylcholine receptor; alpha3/beta2 Ion channel |
Ki | 7.854 | - | Homo sapiens |
| Neuronal acetylcholine receptor; alpha4/beta4 Ion channel |
Ki | 7.64 | - | Homo sapiens |
| Serotonin 3 (5-HT3) receptor Ion channel |
Ki | 4.15 | - | Homo sapiens |
| Acetylcholine receptor; alpha1/beta1/delta/gamma Ion channel |
Ki | 5.83 | - | Homo sapiens |
| Neuronal acetylcholine receptor; alpha3/alpha6/beta2/beta3 Ion channel |
IC50 | 7.07 | - | Homo sapiens |
| Neuronal acetylcholine receptor; alpha2/beta4 Ion channel |
Ki | 7.15 | - | Rattus norvegicus |
| Acetylcholine receptor Ion channel |
Ki | 5.2 | - | Torpedo californica |
| Muscarinic acetylcholine receptor GPCR |
IC50 | 4.55 | - | Rattus norvegicus |
| Acetylcholine receptor subunit alpha Ion channel |
IC50 | 4.68 | - | Homo sapiens |
| Neuronal acetylcholine receptor subunit alpha-3 Ion channel |
IC50 | 7.35 | - | Homo sapiens |
| Transient receptor potential cation channel subfamily A member 1 Ion channel |
EC50 | 5 | - | Mus musculus |
| Potassium voltage-gated channel subfamily D member 3 Ion channel |
IC50 | 7.4 | - | Rattus norvegicus |
SOURCE
DrugCentral 2023 / FAERS disproportionality
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Nicotine dependence | 213 | 1069.634 | 10057852 |
| Macular degeneration | 372 | 962.402 | 10025409 |
| Drug withdrawal syndrome neonatal | 199 | 643.089 | 10013756 |
| Foetal exposure during pregnancy | 406 | 552.523 | 10071404 |
| Drug dependence | 293 | 544.825 | 10013663 |
| Incorrect product administration duration | 179 | 431.698 | 10081581 |
| Overdose | 401 | 319.3 | 10033295 |
| Product adhesion issue | 111 | 308.422 | 10069889 |
| Premature baby | 219 | 302.312 | 10036590 |
| Intentional product misuse | 262 | 275.62 | 10074903 |
| Premature delivery | 137 | 215.378 | 10036595 |
| Dependence | 64 | 189.079 | 10012335 |
| Accidental overdose | 146 | 188.525 | 10000381 |
| Low birth weight baby | 109 | 185.933 | 10067508 |
| Rhesus incompatibility | 36 | 182.481 | 10063676 |
| Chronic sinusitis | 95 | 173.307 | 10009137 |
| Truncus arteriosus persistent | 43 | 169.54 | 10044703 |
| Maternal exposure during breast feeding | 67 | 155.487 | 10080752 |
| Paraesthesia oral | 101 | 153.323 | 10057372 |
| Jaundice neonatal | 50 | 142.921 | 10023138 |
| Application site erythema | 64 | 141.963 | 10003041 |
| Application site pruritus | 58 | 139.112 | 10003053 |
| Procedural pain | 97 | 134.981 | 10064882 |
| Tobacco abuse | 37 | 125.781 | 10043903 |
| Drug abuse | 221 | 122.388 | 10013654 |
| Poor feeding infant | 36 | 119.981 | 10075316 |
| Exposure via breast milk | 50 | 115.588 | 10080751 |
| Foetal disorder | 37 | 108.87 | 10061157 |
| Myocardial stunning | 22 | 103.637 | 10072186 |
| Vaginal flatulence | 41 | 101.747 | 10064227 |
| Maternal exposure during pregnancy | 247 | 95.685 | 10071408 |
| Toxicity to various agents | 378 | 93.28 | 10070863 |
| Congenital cardiovascular anomaly | 30 | 92.666 | 10061054 |
| Application site rash | 38 | 91.518 | 10003054 |
| Ventricular septal defect | 55 | 88.49 | 10047298 |
| Cardiac septal defect | 28 | 84.917 | 10064021 |
| Rheumatoid arthritis | 9 | 82.824 | 10039073 |
| Tobacco poisoning | 17 | 81.746 | 10068887 |
| Rib deformity | 20 | 81.641 | 10059011 |
| Alcohol abuse | 43 | 80.835 | 10001584 |
| Product quality issue | 99 | 78.068 | 10069327 |
| Alopecia | 23 | 77.111 | 10001760 |
| Vaginal discharge | 46 | 76.854 | 10046901 |
| Drug intolerance | 26 | 74.35 | 10061822 |
| Substance abuse | 50 | 73.467 | 10066169 |
| Drug screen positive | 41 | 71.571 | 10049177 |
| Female genital tract fistula | 41 | 71.335 | 10061149 |
| Agitation neonatal | 26 | 69.389 | 10001500 |
| Neutropenia neonatal | 22 | 68.088 | 10029358 |
| Arthropathy | 11 | 67.992 | 10003285 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR ligand-target interactions
7 interactions
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| K v 4.3 Kcnd3 |
Channel blocker | 7.4 pIC50 | 10973847 |
| TRPA1 TRPA1 |
Activation | 4.800000190734863 pEC50 | 19749751 |
| nicotinic acetylcholine receptor α10 subunit CHRNA10 |
Antagonist | - | - |
| nicotinic acetylcholine receptor α3 subunit CHRNA3 |
Agonist | 5.760000228881836 pKi | 32026697 |
| nicotinic acetylcholine receptor α4 subunit CHRNA4 |
Agonist | 8.65999984741211 pKi | 32026697 |
| nicotinic acetylcholine receptor α9 subunit CHRNA9 |
Antagonist | - | - |
| nicotinic acetylcholine receptor α9 subunit CHRNA9 |
Antagonist | - | - |
SOURCE
PharmGKB drug-gene phenotypes
60 phenotype rows
Pharmacogenomics
Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.
CYP2A6 (PA121) CYP2A6*1A, CYP2A6*2, CYP2A6*9, CYP2A6*17
-
Evidence: -; PMID 30706508
OPRM1 (PA31945) rs1799971
-
Evidence: -; PMID 17224915
CYP2A6 (PA121) CYP2A6*1A, CYP2A6*9A, CYP2A6*17, CYP2A6*20, CYP2A6*24A, CYP2A6*26, CYP2A6*27
-
Evidence: -; PMID 18360915
ANKK1 (PA134872551) rs1800497
-
Evidence: -; PMID 15033882
ANKK1 (PA134872551) rs1800497
-
Evidence: -; PMID 21540761
CHRNA3 (PA113) rs1051730
-
Evidence: -; PMID 20886544
CYP2A6 (PA121) CYP2A6*1A, CYP2A6*9A
-
Evidence: -; PMID 12844137
CYP2A6 (PA121) CYP2A6*1A, CYP2A6*4A, CYP2A6*9A
-
Evidence: -; PMID 12844137
CYP2A6 (PA121) CYP2A6*1A, CYP2A6*20
-
Evidence: -; PMID 15993850
CYP2A6 (PA121) CYP2A6*1A, CYP2A6*4A
-
Evidence: -; PMID 11779172
CHRNA5 (PA26491) rs67624739
-
Evidence: -; PMID 29196725
CYP2A6 (PA121) CYP2A6*1A, CYP2A6*4A
-
Evidence: -; PMID 12445030
CHRNA5 (PA26491) rs67624739
-
Evidence: -; PMID 29196725
CYP2A6 (PA121) CYP2A6*1A, CYP2A6*4A, CYP2A6*9A, CYP2A6*10
-
Evidence: -; PMID 22569203
OPRM1 (PA31945) rs1799971
-
Evidence: -; PMID 22260295
DRD2 (PA27478) rs1800497
-
Evidence: -; PMID 26449981
DRD2 (PA27478) rs1800497
-
Evidence: -; PMID 26449981
OPRM1 (PA31945) rs1799971
-
Evidence: -; PMID 26449981
OPRM1 (PA31945) rs1799971
-
Evidence: -; PMID 22046326
CHRNA5 (PA26491) rs16969968
-
Evidence: -; PMID 22046326
CHRM2 (PA111) rs1824024
-
Evidence: -; PMID 19644963
ARRB2 (PA60) rs4790694
-
Evidence: -; PMID 17579607
CYP2A13 (PA27101) rs8192789
-
Evidence: -; PMID 22046326
CYP2A6 (PA121) rs28399433
-
Evidence: -; PMID 11394901
CYP2A6 (PA121) rs28399433
-
Evidence: -; PMID 22046326
CHRNB3 (PA26495) rs6474413
-
Evidence: -; PMID 29621993
CHRNA5 (PA26491) rs667282
-
Evidence: -; PMID 29666375
CHRNA10 (PA26488) rs4575304
-
Evidence: -; PMID 20231857
CYP2A6 (PA121) rs5031016
-
Evidence: -; PMID 11779172
ANKK1 (PA134872551) rs1800497
-
Evidence: -; PMID 15077009
SOURCE
RxNorm drug names
3 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| NICOTINE | 7407 | SU | MTHSPL |
| Nicotine | 7407 | SU | MTHSPL |
| nicotine | 7407 | IN | RXNORM |
SOURCE
SIDER side-effect resource
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abdominal discomfort | nicotine | PT | C0232487 |
| Abdominal discomfort | nicotine | PT | C0232487 |
| Abdominal pain | nicotine | LLT | C0000737 |
| Abdominal pain | nicotine | PT | C0000737 |
| Abdominal pain upper | nicotine | LLT | C0232492 |
| Abdominal pain upper | nicotine | PT | C0232492 |
| Abnormal dreams | nicotine | PT | C0234458 |
| Abnormal faeces | nicotine | LLT | C0162287 |
| Abnormal faeces | nicotine | PT | C0162287 |
| Abnormal vision | nicotine | LLT | C3665386 |
| Acne | nicotine | LLT | C0702166 |
| Acne | nicotine | PT | C0702166 |
| Affect lability | nicotine | PT | C0233472 |
| Agitation | nicotine | LLT | C0085631 |
| Agitation | nicotine | PT | C0085631 |
| Amnesia | nicotine | LLT | C0002622 |
| Amnesia | nicotine | PT | C0002622 |
| Anaphylactic shock | nicotine | LLT | C0002792 |
| Anaphylactic shock | nicotine | PT | C0002792 |
| Angioedema | nicotine | LLT | C0002994 |
| Angioedema | nicotine | PT | C0002994 |
| Anxiety | nicotine | LLT | C0003467 |
| Anxiety | nicotine | PT | C0003467 |
| Apathy | nicotine | LLT | C0085632 |
| Apathy | nicotine | PT | C0085632 |
| Aphasia | nicotine | LLT | C0003537 |
| Aphasia | nicotine | PT | C0003537 |
| Aphthous stomatitis | nicotine | LLT | C0038363 |
| Aphthous stomatitis | nicotine | PT | C0038363 |
| Aphthous stomatitis | nicotine | LLT | C0038363 |
| Aphthous stomatitis | nicotine | PT | C0038363 |
| Application site reaction | nicotine | LLT | C0151505 |
| Application site reaction | nicotine | PT | C0151505 |
| Arrhythmia | nicotine | LLT | C0003811 |
| Arrhythmia | nicotine | PT | C0003811 |
| Arthralgia | nicotine | LLT | C0003862 |
| Arthralgia | nicotine | PT | C0003862 |
| Arthritis | nicotine | LLT | C0003864 |
| Arthritis | nicotine | PT | C0003864 |
| Asthenia | nicotine | LLT | C0004093 |
| Asthenia | nicotine | PT | C0004093 |
| Asthenia | nicotine | PT | C0004093 |
| Atrial fibrillation | nicotine | LLT | C0004238 |
| Atrial fibrillation | nicotine | PT | C0004238 |
| Atrial fibrillation | nicotine | LLT | C0004238 |
| Atrial fibrillation | nicotine | PT | C0004238 |
| Back pain | nicotine | LLT | C0004604 |
| Back pain | nicotine | PT | C0004604 |
| Bladder pain | nicotine | PT | C0232849 |
| Blister | nicotine | LLT | C0005758 |
| Blister | nicotine | PT | C0005758 |
| Blood pressure fluctuation | nicotine | PT | C0549405 |
| Blood pressure increased | nicotine | LLT | C0497247 |
| Blood pressure increased | nicotine | PT | C0497247 |
| Body temperature increased | nicotine | LLT | C0015967 |
| Body temperature increased | nicotine | PT | C0015967 |
| Bronchitis | nicotine | LLT | C0006277 |
| Bronchitis | nicotine | PT | C0006277 |
| Bronchospasm | nicotine | LLT | C0006266 |
| Bronchospasm | nicotine | PT | C0006266 |
| Burning sensation | nicotine | LLT | C0085624 |
| Burning sensation | nicotine | PT | C0085624 |
| Cardiac disorder | nicotine | LLT | C0018799 |
| Cardiac disorder | nicotine | PT | C0018799 |
| Cardiac failure | nicotine | LLT | C0018801 |
| Cardiac failure | nicotine | PT | C0018801 |
| Cerebration impaired | nicotine | LLT | C0235198 |
| Change in blood pressure | nicotine | LLT | C1268766 |
| Chest discomfort | nicotine | PT | C0235710 |
| Chest discomfort | nicotine | LLT | C0235710 |
| Chest discomfort | nicotine | PT | C0235710 |
| Chest pain | nicotine | LLT | C0008031 |
| Chest pain | nicotine | PT | C0008031 |
| Chest pain | nicotine | PT | C0008031 |
| Chest tightness | nicotine | LLT | C0232292 |
| Cold sweat | nicotine | LLT | C0232431 |
| Cold sweat | nicotine | PT | C0232431 |
| Completed suicide | nicotine | PT | C0852733 |
| Confusional state | nicotine | LLT | C0009676 |
| Confusional state | nicotine | PT | C0009676 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Nicotine used for in pharmaceutical contexts?
Nicotine (CAS 54-11-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Nicotine?
Nicotine has 1,039 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Nicotine dependence, Macular degeneration, Drug withdrawal syndrome neonatal, Foetal exposure during pregnancy, Drug dependence. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Nicotine also used in cosmetics?
No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Nicotine.
What clinical phase is Nicotine in?
Nicotine is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Nicotine?
Nicotine has 48 bioactivity rows in this page query. Rendered target entries include Neuronal acetylcholine receptor subunit alpha-7, Potassium voltage-gated channel subfamily D member 3, Cytochrome P450 2A6, Acetylcholine-binding protein, Transient receptor potential cation channel subfamily A member 1.